B. Riley Has Bearish Forecast for Immunic FY2024 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at B. Riley reduced their FY2024 EPS estimates for Immunic in a research report issued on Tuesday, November 26th. B. Riley analyst W. Wood now anticipates that the company will post earnings of ($0.97) per share for the year, down from their prior estimate of ($0.93). B. Riley currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share. B. Riley also issued estimates for Immunic’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($0.80) EPS.

Several other equities research analysts have also recently weighed in on the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research note on Monday, September 16th. Leerink Partners restated an “outperform” rating and set a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. HC Wainwright initiated coverage on shares of Immunic in a report on Monday. They issued a “buy” rating and a $10.00 target price for the company. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.20 on Thursday. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The stock has a market cap of $108.10 million, a P/E ratio of -0.98 and a beta of 1.88. The stock has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $1.34.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of IMUX. State Street Corp raised its holdings in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Immunic during the 1st quarter worth approximately $25,000. Jane Street Group LLC lifted its holdings in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Immunic

In related news, Director Richard Alan Rudick purchased 87,300 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.